Home > News > RSS Feed World News >
Prostate cancer drugs linked to increased risk of metabolic and cardiovascular issues
Prostate cancer drugs linked to increased risk of metabolic and cardiovascular issues
Share This
Twitter
Facebook
Research published in the Journal of the National Cancer Institute indicates that men with advanced prostate cancer who are prescribed abiraterone and enzalutamide may have an increased risk of metabolic and cardiovascular problems.
Our website uses cookies to provide you with a better online experience.
If you continue to use our site without changing your browser settings,
we'll assume you are happy to receive cookies.
Please read our cookie policy for more information.